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Summary 
The 60 kDa tumor necrosis factor receptor (TNF&) is 
regarded as the major signal transducer of TNF- 
induced cellular responses, whereas the signal capac- 
ity and role of the 80 kDa TNFR (TNFR,,) remain largely 
undefined. We show here that the transmembrane 
form of TNF is superior to soluble TNF in activating 
TNFRso in various systems such as T cell activation, 
thymocyte proliferation, and granulocyte/macrophage 
colony-stimulating factor production. Intriguingly, ac- 
tivation of TNFRso by membrane TNF can lead to quali- 
tatively different TNF responses such as rendering 
resistant tumor cells sensitive to TNF-mediated cyto- 
toxicity. This study demonstrates that the diversity of 
TNF effects can be controlled through the differential 
sensitivity of TNFRao for the two forms of TNF and sug- 
gests an important physiological role for TNFRso in lo- 
cal inflammatory responses. 
Introduction 
Tumor necrosis factor (TNF) is a pleiotropic cytokine that 
is primarily produced by activated macrophages and lym- 
phocytes, but is also expressed in endothelial cells and 
other cell types. TNF represents a major mediator of in- 
flammatory, immunological, and pathophysiological reac- 
tions (reviewed by Fiers, 1991; Adolf et al., 1994). Kriegler 
et al. (1988) have demonstrated that the presumed atypi- 
cal leader sequence of TNF in fact represents a transmem- 
brane domain. Accordingly, two distinct species of the mol- 
ecule exist: the 26 kDa membrane-expressed form of TNF 
(mTNF) and the soluble 17 kDa cytokine (sTNF), which is 
derived from proteolytic cleavage of the 26 kDa membrane 
form. Despite this precursor/product relationship of the 
two TNF forms, it was soon demonstrated that mTNF is, in 
principle, bioactive and confers, in situations of juxtracrine 
intercellular signaling, typical TNF responses such as cy- 
totoxicity (Perez et al., 1990) or B lymphocyte activation 
(Aversa et al., 1993). 
Two distinct membrane receptors for TNF of apparent 
molecular weight 55-60 kDa (TNFRGO) and 70-80 kDa 
(TNFRso) have been identified and molecularly cloned. 
Both receptors have significant homologies in their extra- 
cellular domains with repeat cysteine-rich sequences, de- 
fining them as members of a novel, large receptor family 
(reviewed by Smith et al., 1994). Most cell lines and pri- 
mary tissues coexpress both receptor types, although ex- 
pression of TNFRso and TNFRso is controlled by distinct 
mechanisms. Typically, TNFRso is constitutively expressed 
at a rather low level, whereas the level of TNFRao expres- 
sion is subject to both transcriptional and posttranscrip- 
tional regulation induced by external stimuli (Thomaet al., 
1990; Brockhaus et al., 1990). 
Recently, different TNFRBo- and TNFRso-associated pro- 
teins have been characterized and molecularly cloned 
(Hsu et al., 1995; Rothe et al., 1994), suggestive of an 
independent role of both receptors in separate cellular 
responses. This prediction, however, contrasts with the 
current model of the apparent dominance of TNFRGO in 
TNF signaling including accumulation of c-fos, interleu- 
kin-6 (IL-6), and manganese superoxide dismutase mRNA, 
synthesis of prostaglandin EP, IL-2 receptor, and MHC 
class I and II antigen expression, growth inhibition, and 
cytotoxicity (reviewed by Adolf et al., 1994). Furthermore, 
it has been demonstrated in various in vitro and in vivo 
models that TNFRGO induces cellular TNF responses inde- 
pendent of TNFR8,, stimulation (Engelmann et al., 1990; 
Pfeffer et al., 1993). 
The contribution of TNFR,, to cellular responses in- 
duced by sTNF appeared to be, by and large, of a sup- 
portive or modulating nature, with two distinct functional 
properties. First, the proteolytically cleaved extracellular 
domain may buffer excessive sTNF and, as a conse- 
quence, might be effective as a TNF inhibitor (Porteau 
and Hieblot, 1994). Second, TNFRsa-bound ligand may be 
passed over to TNFRso to enhance TNFRso signaling, a 
process termed ligand passing that is favored by the dis- 
tinct kinetics of ligand association and dissociation of the 
two receptors (Tartaglia et al., 1993b). Aside from these 
features, only a few examples have been described in 
which a TNFRso-independent, TNFRBO-mediated cellular 
response was induced by sTNF, namely granulocytelmac- 
rophage colony-stimulating factor (GM-CSF) expression 
in a T cell hybridoma (Vandenabeele et al., 1992) and 
proliferation of thymocytes (Tartaglia et al., 1991, 1993a). 
In addition, independent activation of intracellular signal- 
ing cascades by TNFRso was readily demonstrated in a 
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number of experirnental models when TNF!& overexpres- 
sion systems were studied or TNFR,,,-specific antibodies 
were used (Tartaglia et al., 1991; Heller et al., 1992; Van- 
denabeeleetal.,1992;Gehretal.,1992;Grelletal.,1993). 
The physiological significance of these findings, however, 
remained uncertain. 
The present work provides a new basis for the compre- 
hension of TNF-TNFRBO interaction and function. In par- 
ticular, we have discovered that TNF& can be strongly 
stimulated by mTNF rather than by sTNF, suggesting that 
mTNF is the prime physiological activator of TNFRBO. As 
mTNF also signals via TNFRGO, the resulting cooperativity 
of both receptors leads to cellular responses much 
stronger than those achievable with sTNF alone. More- 
over, we show that upon appropriate activation of TNFRBO, 
a phenotypic switch of the cellular response pattern to 
TNF can be observed, such that, as an example, cells fully 
resistant to the cytotoxic action of sTNF become highly 
susceptible and are killed upon contact with mTNF. 
Results 
Cellular Responses to sTNF Are Dominated 
by TNFRGO 
To clarify the functional role of TNFRa,, in TNF responses, 
we used mutants of the TNF molecule (muteins) that have 
previously been demonstrated to interact specifically with 
only one of the two TNFRs and, hence, represent efficient 
receptor-selective tools (Loetscher et al., 1993). The ability 
of each of the two TNFRs to mediate an independent cellu- 
lar signal was studied in three different cell types predomi- 
nantly expressing TNFRBo that had been shown to be in- 
volved in TNF signaling by inhibition with receptor-specific 
antagonistic antibodies (Scheurich et al., 1992; Grell et al., 
1993). These studies had indicated an auxiliary function 
of TNFRB~ in TNFRsO-controlled cellular responsiveness, 
although at that time the mechanism remained unre- 
solved. 
In accordance with these earlier studies, a dominant 
role of TNFRw was also revealed using the receptor- 
specific TNF muteins. In particular, the TNFR,-specific 
mutein induced cytotoxicity in the cell line KYM-1, en- 
hanced interferon-y (IFNy)-induced HLA-DR expression in 
the cell line Co10205 and up-regulated HLA-DR expres- 
sion in activated human peripheral blood T cells (Figures 
l A-l C). The magnitude of these responses was compara- 
ble to that of wild-type TNF, although somewhat higher 
concentrations of the mutein were needed. In contrast, 
the TNFRBO-specific mutein was unable to induce a re- 
sponse in Co10205 cells and in activated T cells (Figures 
1 B and 1 C), and only a small cytotoxic effect was observed 
in KYM-1 cells at high TNF mutein concentrations up to 
10 nM (Figure 1A). 
Antibodies Are Superior to sTNF in Stimulation 
of TNFR80 
The predominant role of TNFRso in the aforementioned 
TNF responses was confirmed using agonistic antibodies. 
In all three systems, the TNFRso-specific agonistic mono- 
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Figure I. Disparity between TNF and Receptor-SpecificAgonisticAnti- 
bodies to Induce Cellular Responses via TNFR,, 
The induction of cytotoxicity in KYM-I ceils (A and D), enhancement 
of HLA-DR antigen expression in activated peripheral blood T lympho- 
cytes (6 and E), and enhancement of IFNy-induced HLA-DR expres- 
sion in Co10205 cells (C and F) was determined as described in the 
Experimental Procedures. 
(A-C) Cells were treated with serial dilution of recombinant human 
TNF, a TNFRso-specific TNF mutant (TNFnslw.sasr), and a TNFRso- 
specific TNF mutant (TNFD143N.,,145R). 
(D-F) Cells were stimulated with the agonistic MAb Htr-1 (100 = hy 
bridoma supernatant 1:lOO) and TNFRao-specific purified rabbit IgG 
(10’ = 40 rig/ml). Matched control antibodies showed no effect in any 
of the cellular systems. The results are representative for at least three 
independent experiments. 
clonal antibody (MAb) Htr-1 could induce comparable re- 
sponses (Figures 1 D-l F). However, in contrast with the 
complete lack or inefficient stimulation of cells by the 
TNFR,o-specific TNF mutein, TNFRBO-specific agonistic 
antibodies could efficiently induce cytotoxicity in KYM-1 
cells (Grell et al., 1994; Figure 1 D) and enhance HLA-DR 
expression in activated T cells (Figure lE), indicating a 
superior efficacy of antibodies in TNFRBO stimulation as 
compared with sTNF. 
In the cell line Colo205, selective TNFRao triggering by 
specific antibodies could not enhance HLA-DR expression 
(Figure 1 F), making questionable the signaling capability 
of TNFR80 in these cells. To analyze whether antibody 
TNF&, Activation by Membrane TNF 
795 
1.4 g 
1.0 g 
!I 
0.6 ; 
0.2 s 
0 IO-2 10-1 100 0 IO' 102 103 
Agonistic antibody (dilution) TNF (PM) 
Figure 2. Antibody-Mediated Hyperstimulation of TNFRBo Changes the 
Cellular Response Pattern of Co10205 Cells 
(A)AntibodystimulationofTNFReodoesnotenhanceTNFRw-mediated 
up-regulation of HLA-DR expression. Co10205 cells were treated for 
40 hr with TNFRso-specific MAb Htr-1 (IO0 = hybridoma supernatant 
1 :I 00) in the absence (open squares) or presence (closed squares) 
of agonistic TNFR,,-specific rabbit IgG (10 pglml). The assay was per- 
formed in the presence of 30 pg/ml IFNy, and expression of HLA-DR 
was assessed by direct flow cytometric analysis. Shown is the specific 
fluorescence mean channel number after subtraction of values deter- 
mined by a matched control antibody. Asterisks indicate cultures with 
>50% dead cells after 40 hr as determined by vital exclusion dye. 
(B) Induction of cytotoxicity by costimulation with TNF and TNFRso- 
specific antibodies. Co10205 cells were incubated in triplicates for 40 
hr with serial dilutions of TNF in the absence (open triangles) or pres- 
ence of TNFRso-specific MAb Htr-1 (hybridoma supernatant, i:lOO, 
open squares), TNFR,-specific rabbit serum (1:200, closed squares), 
and the TNFR80-specific MAb 60M2 (5 pg/ml, closed triangles). 
costimulation of TNF!& in the presence of TNFFIW stimu- 
lation could lead to cooperation with the TNFRso-mediated 
response, Co10205 cells were simultaneously treated with 
both TNFl&-specific and TNFR,-specific agonistic anti- 
bodies. This type of stimulation did not lead to an enhance- 
ment of HLA-DR expression triggered by TNFRso (Figure 
2A), but surprisingly induced a strong cytotoxic effect in 
Co10205 cells (Figure 2B). Obviously, antibody costimula- 
tion of both TNFRs in Co10205 cells had changed the cellu- 
lar response pattern from an immunostimulatory type (i.e., 
up-regulation of HLA-DR antigens) to one that induces 
cytotoxicity. This is remarkable because cytotoxicity in 
Co10205 cells could not be induced by sTNF alone, even 
with high concentrations (Figure 28). The observed change 
in response pattern was apparently caused by an anti- 
body-mediated hyperstimulation of TNFRBO, as Co10205 
cells were efficiently killed by TNF in a dose-dependent 
manner in the presence of agonistic TNFRso-specific anti- 
bodies or the nonagonistic TNFRBO-specific MAb 80M2. By 
contrast, costimulation of the cells with TNF and various 
different TNF&specific, agonistic MAbs, Htr-1 (Figure 
2B), Htr-9, and Htr-2 (data not shown), proved to be ineffec- 
tive in this regard. 
The Hyperstimulating TNFReo-Specific MAb 80M2 
Stabilizes the Ligand-Receptor Complex 
To examine the mechanism by which the nonagonistic 
MAb 80M2 causes a hyperstimulation of TNFRso in the 
presence of sTNF, we tested this MAb together with the 
TNFRso-specific mutein. In all three cellular systems, co- 
stimulation of the cells induced a response similar to that 
obtained with the agonistic TNFRsa-specific antibodies. In 
particular, the presence of MAb 80M2 potentiated the 
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Figure 3. TNFRsO-Dependent Responses to sTNF Are Substantially 
Enhanced by MAb 60M2 
Assay systems to determine induction of cytotoxicity in KVM-1 cells 
(A) and ColoZO5 cells (C) and enhancement of HLA-DR antigen expres- 
sion in activated peripheral T lymphocytes (B) were performed as de- 
scribed in the Experimental Procedures. Cells were treated with a 
TNFR,-specific TNF mutein in the absence (open circles) or presence 
of MAb 60M2 (5 Kg/ml, closed circles). Strong responses were ob- 
tained upon costimulation with the MAb 60M2 in KVM-1 and T cells, 
whereas in Co10205 cells an additional costimulation of TNFReo with 
a TNFRm-specific TNF mutein (TNFR32W-S66T, 50 nglml) was neces- 
sary to induce cytotoxicity (C, closed squares). A combination of both 
TNF muteins in Co10205 cells in the absence of MAb 60M2 was ineffec- 
tive (open triangles). 
TNFR,,-specific mutein-induced cytotoxicity in KYM-1 
cells (Figure 3A) and rendered activated T cells sensitive 
to TNFRao-specific mutein-induced HLA-DR expression 
(Figure 38). In accordance with the results using agonistic 
antibodies (Figure 2B), only the adequate stimulation of 
both TNFRs caused cytotoxicity in Co10205 cells: a combi- 
nation of the TNFRW-specific and TNFR,,+pecific muteins 
exerted a strong cytotoxic effect only in the presence of 
the MAb 80M2 (Figure 3C). 
Because MAb 80M2 is per se neither agonistic nor an- 
tagonistic (Grell et al., 1993) we analyzed whether MAb 
80M2 would affect the binding properties of sTNF to 
TNFRw Kinetic studies with iodinated TNF at 37% re- 
vealed that preincubation of cells with 80M2 led to astrong 
reduction in the dissociation rate constant (Ken, Figures 
4A and 48) whereas the association rate constant (KO,,) 
was almost unchanged (Figure 4B). Accordingly, MAb 
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Figure 4. inhibition of Ligand Dissociation by the Antibody 80M2 
(A) Time course of TNF dissociation from TNF& at 37OC. KYM-1 cells 
were incubated for 1 hr with 0.5 nM [‘Z51JTNF at 4OC in the presence 
(closed circles) or absence of 80M2 (open circles), and subsequently, 
dissociation of radioiodinated ligand was determined at 37’C in the 
presence 50 nM unlabeled TNF. 100% pz51]TNF binding equalled to 
6,617 cpm (control) and 13,322 cpm (with 80M2). Nonspecific binding 
in the presence of a 1 OO-fold excess of unlabeled TNF was determined 
at several timepoints, and revealed values were 150 cpm. 
(B) Comparison of [‘251]TNF binding data in the absence or presence 
of MAb 80M2. Dissociation rate constants and half-life time values 
of bound [“?]TNF were calculated as described in the Experimental 
Procedures. In addition, the association rate constants derived from 
association kinetics experiments are shown as well as the calculated 
values for the dissociation constants (Kd = K&J. Mean values of 
two independent experiments are presented. Similar differences 
caused by MAb 80M2 in TNF dissociation but not TNF association 
rate constants were found using Co10205 cells (data not shown). 
80M2 raises the affinity of TNF!+ for sTNF more than 
1 O-fold as revealed from the calculated dissociation con- 
stant (Kd) values (Figure 4B). These data suggest that the 
altered signaling capability of TNFRBO induced by TNF in 
the presence of MAb 80M2 is linked to the change in ligand 
binding characteristics. 
The Transmembrane Form of TNF Strongly 
Activates TNF& 
The finding that prolonged binding of TNF to TNFRr,O 
caused by MAb 80M2 is associated with signal capability 
of this receptor prompted us to look for potential physiolog- 
ical correlates. In particular, we asked whether this experi- 
mental setting simply mimics the biological effects of the 
membrane-anchored form of TNF, which has been shown 
to possess bioactivity (Perez et al., 1990). To that end, we 
transfected Chinese hamster ovary (CHO) cells with the 
DNA coding for wild-type human TNF. The resulting cell 
clones expressed mTNF, as revealed by cytofluorometric 
analysis (data not shown) and immunofluorescence mi- 
croscopy(Figure5E). In fact, Colo205cellswereefficiently 
killed when cocultivated with TNF-transfected CHO cells 
(Figure 5B), but not with control CHO cells in the presence 
of sTNF (Figure 5A). To ensure that the observed cytotox- 
icity is mediated by the membrane-expressed cytokine 
alone, without any effect of sTNF, we generated an un- 
cleavable TNF deletion mutant by site-directed mutagene- 
sis as described previously (Perez et al., 1990). Similarly, 
CHO cells transfected with this mutant expressed mTNF 
(Figure 5F) and lysed Co10205 cells very efficiently (Figure 
5C). No sTNF was detectable in the supernatant of such 
cocultures, as revealed by highly sensitive bioassays (data 
not shown). The capability of mTNF-expressing CHO 
clones to induce cytotoxicity in Co10205 cells does not 
require strong overexpression of the mTNF molecule, be- 
cause independently isolated transfectants, expressing 
mTNF at various levels between about 1000 and 30000 
molecules per cell, as estimated from fluorescence- 
activated cell sorting (FACS) analysis, induced cytotoxicity 
in Co10205 cells (data not shown). Similar results were 
obtained using an additional, independently generated 
cell line, NIH 3T3+12jT~~, also expressing the uncleavable 
mutant form of TNF (Perez et al., 1990), as well as with 
transiently transfected COSl cells using the same DNA 
construct (data not shown). The specificity of these effects 
was demonstrated further using neutralizing anti-TNF anti- 
bodies, which completely abrogated the cytotoxic effects 
(Figure 5G). Accordingly, mTNF possesses the capability 
to activate TNFRs of Co10205 cells in a similar way as 
the MAb 80M2 in the presence of sTNF. The induction of 
cytotoxicity in Co10205 cells was inhibited by antagonistic 
antibodies directed against either of the TNFRs (Figure 
5G), indicating that both TNFRso and TNFRsa are involved 
in mTNF signaling in this particular cellular response. 
Next, we probed into whether the phenomenon of hy- 
perresponsiveness due to TNFRBO activation could also 
be observed in thymocytes, a cellular system in which 
sTNF effects have been demonstrated to be initiated by 
TNFRao independently of TNFRGO (Tartaglia et al., 1991, 
1993a). To analyze TNF responses attributed to TNFRao 
such as proliferation and GM-CSF production (Tartaglia 
et al., 1991; Vandenabeele et al., 1992), we took advan- 
tage of the fact that human TNF does not bind to murine 
TNFRB~. Therefore, we used mouse thymocytes from 
transgenic mice generated to express selectively the hu- 
man TNFRaO under the control of the CD2 promoter in the 
Tcell compartment (E. D., unpublished data). Thymocytes 
of these mice constitutively expressed the human TNFRao 
in the range of 1000-2000 molecules/cell as determined 
by FACS and saturation binding analyses using human 
TNFRB,-specific antibodies and iodinated human TNF, re- 
spectively (data not shown). In contrast with thymocytes 
of nontransgenic littermates (data not shown), human 
TNFRs, transgenic thymocytes responded well to the stim- 
ulation with human sTNF in all parameters of thymocyte 
activation analyzed, i.e., cell proliferation, up-regulation 
of IL-2 receptor a chain (CD25), and GM-CSF production 
(Figures 6A-6C). Stimulation of transgenic thymocytes 
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Figure 5. The Transmembrane Form of TNF Induces Cytotoxicity in 
Co10205 Cells 
Control CHO cells (A and D) or CHO cells transfected with the wild-type 
human TNF DNA (CHOWnvF) (B and E) or the DNA for an uncleavable 
mutant transmembrane form of TNF (CHObll.IPjTNF) (C and F) were 
cultured to form monolayers. Membrane expression of TNF on CHO 
cells (D), CHOwtTNF cells (E), and CHO b(, lqTNF cells (F) was visualized 
by fluorescence microscopy using a FITC-conjugated anti-membrane 
TNF antibody (R&D Systems). For cell-to-ceil killing experiments, 
Co10205 cells were added to the cultures in the absence (B and C) or 
presence (A) of sTNF (1 nM), and photographs were taken after 24 
hr. Co10205 cells do not spread out on the culture vessel (inset of A) 
or CHO monolayer and are easily distinguishable from the adherent 
CHO cells. Scale bars represent 50 Frn. 
(G) Both TNFRs are essential for mTNF-induced cytotoxicity in 
Co10205 cells. Irradiated CHO cells or CHOb,l.IZjTNF cells were co- 
cultured for 30 hr with Co10205 cells in the absence or presence of 
0.2 nM TNF, 30 vg/ml neutralizing anti-TNF MAb, 50 pg/ml antago- 
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Figure 6. Stimulation of Thymocytes by the Transmembrane Form of 
TNF 
Thymocytes of human TNFR,-transgenic mice were isolated and cul- 
tured in the presence of 0.5 pg/ml concanavalin A on a monolayer of 
control CHO ceils without or with titrated concentrations of human 
sTNF (stippled bars). The results from groups with maximal response 
to sTNF are shown (0.5-l nM). In parallel, cocultures were set up 
with thymocytes and CHOI(l.IPjTNF cells (closed bars) alone or in the 
presence of antagonisticTNFR,-specificantibodies. After40 hr, prolif- 
erative responses were determined by (3H]thymidine incorporation (A), 
expression of murine CD25 was analyzed by cytofluorometry (B), and 
murine GM-CSF secretion was determined from culture supernatants 
by ELISA (C) as described in the Experimental Procedures. Data of 
experimental groups are presented as stimulation of untreated con- 
trols (means & SEM of three independent experiments). The respec- 
tive values of untreated control groups in individual experiments were 
2758, 2346, and 4103 cpm per IO6 cells (proliferation assay), 34, 49, 
and 11 arbitrary fluorescence units (CD25 expression, mean channel 
number) and 35, 40, and 23 pglml (GM-CSF production). 
with mTNF in all three assays led to a stronger response 
than with saturating concentrations of sTNF (17.9-fold ver- 
sus 6.1-fold stimulation of proliferation, Figure 6A; 3.6-fold 
versus 1.7-fold stimulation of CD25 expression, Figure 66; 
4.7-fold versus 2.3-fold stimulation of GM-CSF production, 
Figure 6C). TNFRBo transgene dependence in mediating 
these responses was verified by inhibition with TNFRso- 
specific antagonistic antibodies (Figures 6A-6C). 
nistic Fab fragments of polyclonal TNFR,-specific antibodies, or 30 
pglml antagonistic TNFRso-specific MAb H398. [3H]thymidine incor- 
poration was determined as described in the Experimental Proce- 
dures. 13H]thymidine background uptake of irradiated CHO cells or 
~~~~~~~~~~~~~ cells alone is subtracted in the figure (3331 and 3725 
cpm, respectively). 
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Further evidence for the physiological importance of 
the superiority of mTNF over sTNF in the triggering of 
TNF& comes from experiments using cells from normal 
human tissues. First, we analyzed activated human pe- 
ripheral bloodTlymphocytesforwhichTNF has beendem- 
onstrated to act as a costimulatory molecule (Scheurich 
et al., 1987). Coculture of activated T cells with CHO cells 
expressing the noncleavable membrane form of TNF re- 
sulted in a significantly stronger up-regulation of HLA-DR 
expression than coculture with control CHO cells in the 
presence of saturating concentrations of sTNF (Figure 
7A). The critical involvement of TNFRso in this hyperstimu- 
lation was demonstrated by the fact that costimulation with 
MAb 80M2 greatly enhanced the response by the TNF!&- 
specific mutein (Figure 3B), or by wild-type TNF resulting 
in an approximately 3-fold increase over the maximal re- 
sponse induced by saturating TNF concentrations in the 
presence of 80M2 versus TNF alone (289% r 103%, 
eight different blood donors; data not shown). 
Second, we compared the reactivity of human umbilical 
vein endothelial cells (HUVECs) toward sTNF and mTNF 
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Figure 7. Stimulation of Normal T Lymphocytes and Endothelial Cells 
by mTNF 
(A) PHA-activated peripheral blood T lymphocytes were cultured for 
40 hr without any further additions (open bar), or on a monolayer of 
control CHO cells (stippled bars) without or with sTNF. sTNF was 
titrated, and data of the TNF concentration (2 nM) resulting in the 
maximal response are shown. In parallel, T ceils were cultured on a 
monolayer of CHO~~I.lZ~TNFcells (closed bars) without or with antagonis- 
tic antibodies as indicated. HLA-DR antigen expression of the T cells 
was determined by direct cytofluorometry. 
(6) HUVECs were left untreated (open bar), or stimulated for 3 hr by 
the addition of CHO cells (stippled bars) in the absence or presence 
of saturating concentrations of sTNF (2nM), or by the addition of 
CHO~~l.IP~TNF cells (closed bars) in the absence or presence of the indi- 
cated antagonistic antibodies. Subsequently, tissue factor production 
was determined as described in the Experimental Procedures. Pre- 
sented values are the means of triplicates. 
for the following reasons: these cells, comprising the lining 
of the vasculature, play a crucial role in local inflammatory 
processes that are, in part, controlled by TNF (Pober and 
Cotran, 1990); recent data have implicated both TNFRs 
in the induction of prothrombotic tissue factor expression 
(Schmidt et al., 1995b), which is a key event in coagulation 
both in the course of septic shock and in local tissue necro- 
sis; a role of TNFReo in TNF-induced skin necrosis is appar- 
ent from experiments employing TNFRso gene knockout 
mice (Erickson et al., 1994). In a direct comparison, the 
coculture of HUVECs with mTNF-expressing cells for 3 
hr led to a significantly higher tissue factor expression than 
could be achieved even with saturating concentrations of 
sTNF (Figure 7B). The involvement of both receptors in 
this mTNF response is evident from the efficient inhibition 
by antagonistic antibodies directed against each of the 
two receptors (Figure 78). 
Based on the data presented, a model of the functional 
role of the two TNFRs is proposed that takes into account 
the differential interplay of the soluble versus the mem- 
brane-expressed form of the ligand with each of the two 
receptors (Figure 8). Typically, TNFRso is the main media- 
tor of a wide array of effects induced by sTNF. Binding of 
sTNF accounts for TNF responses upon application of 
soluble, recombinant TNF or upon endogenous TNF pro- 
duction at a timepoint when TNF has been processed and 
released into the body fluids. An appealing feature of the 
novel model described here is the fact that mTNF is the 
physiological precursor of sTNF and thus could be an early 
and very effective stimulus because it could induce inde- 
pendent signal pathways at each of the TNFRs. This signal 
is dependent on cell-to-cell contact and is thus locally re- 
stricted. Depending on whether the juxtaposition of mTNF 
and TNFRs involves just one or both receptor types on the 
same cell, the quality and quantity of the induced cellular 
response may therefore differ strikingly. 
Ligand Passing Cooperative Signaling 
Signal high low high high 
I \/ 
Response 1 Response 1 
Response 2 
Figure 8. Model of the Functional Role of TNFReo 
The model proposes the major functional roles of TNFf% in response 
to sTNF (left) and mTNF (right). 
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Discussion 
Based on numerous in vitro and in vivo studies, a predomi- 
nant role of TNFRso in mediating TNF responses became 
apparent, whereas the contribution of the coexpressed 
TNFF& remained, by and large, unclear. With the data 
presented here showing that TNFRso defines the quality 
and quantity of cellular responses to mTNF, we provide 
evidence that the functional significance of TNFFtso has 
been grossly underestimated. We propose that mTNF 
rather than sTNF is the prime physiological activator of 
TNFRso, which implies that TNFRso controls the local re- 
sponse pattern in the microenvironment of tissues reactive 
to external stimuli with endogenous TNF expression. 
Retrospectively, earlier assessments of the functional 
role of the two TNFR were biased toward a TNFRso domi- 
nance because of the use of exogenous or induction of 
endogenous sTNF. Although under these conditions an- 
tagonistic TNFRso-specific antibodies partially blocked 
TNF responses, such as activation of NF-KB, up- 
regulation of adhesion molecules, and HLA-DR expres- 
sion, TNFReo-selective agonists failed to induce the very 
same responses (Shalaby et al., 1990; Scheurich et al., 
1992; Mackay et al., 1993). Recently, the participation of 
TNFRso in TNF responses has been attributed to the ability 
of TNFRso to raise the virtual TNF concentration in the 
proximity of TNFRso and, therefore, to enhance signaling 
of the latter receptor (the model of ligand passing by Tar- 
taglia et al., 1993b). Such an accessory function of TNFRso 
could be envisaged due to its higher affinity for TNF com- 
pared with TNFRso and is, in particular, based on its fast 
ligand association and dissociation kinetics. Therefore, 
ligand passing is expected to be most effective at low con- 
centrations of sTNF. According to this model and in 
agreement with experimental data obtained in the majority 
of in vitro systems, TNF responses appear to be limited 
by ligand interaction with TNFRso without significant gener- 
ation of an intracellular signal by TNFRso. 
The availability and application of novel, TNFReo- 
specific antibodies with agonistic activity shed new light 
onto this question by showing that TNFRso can directly 
induce cellular responses independent of TNFRso (Tartag- 
lia et al., 1991; Gehr et al., 1992; Grell et al., 1993). We 
have here directly compared TNF muteins that have exclu- 
sive specificity for either TNFRso or TNFRBo with TNFR- 
specific agonistic antibodies and show that antibody stim- 
ulation is a more potent stimulus for TNFRso than sTNF 
(Figure 1). The inefficiency of the TNFRso-specific TNF 
mutein to induce cytotoxicity in KYM-1 cells and the com- 
plete inability to elicit a response in activated human T 
cells could not be attributed to the lack of binding, as the 
mutein exerts only a slightly reduced affinity to TNFRso 
when compared with wild-type TNF (Loetscher et al. 1993; 
data not shown) and has been applied up to saturating 
concentrations. However, in both cell types, the principal 
signaling capability of TNFRBo could be demonstrated us- 
ing either a TNFRso-specific agonistic polyclonal immuno- 
globulin G (IgG) from rabbit (Figures 1D and 1E) or a 
TNFRso-specific monoclonal antibody MR2-1 (data not 
shown). This perceived superiority of antibody triggering 
of TNFReo over TNF is in accordance with an earlier report 
showing a stronger stimulation of human thymocyte prolif- 
eration with agonistic antibodies compared with TNF (Tar- 
taglia et al., 1993a). 
The mechanism by which antibodies can act as TNFRso 
agonists is most likely to be based on the fact that dimeriza- 
tion of TNFRso is an obligatory step for induction of signal 
cascades (Grell et al., 1993). Obviously, similarily to TNF, 
antibodies can readily dimerize TNFReo because of their 
bivalency and flexibility in antigen binding. The difference 
between sTNF and agonistic antibodies in the potency to 
induce a cellular response could be related to the different 
binding kinetics. Whereas the dissociation kinetics of 
sTNF from TNFR8o is extremely rapid at 37% (Figure 4), 
the dissociation kinetics of antibodies from TNFRBo were 
several orders of magnitude slower (data not shown). The 
underlying molecular mechanisms of this differential 
TNFRso activation by sTNF versus agonistic antibodies is, 
at present, not understood. Considering that the associa- 
tion/dissociationstepsof intracellularsignalingmolecules, 
like the recently defined TNF receptor-associated pro- 
teins (TRAFs, Rothe et al., 1994) could be response lim- 
iting in TNFR80 signaling, it is feasible that an increased 
stabilityof receptorcomplexformation byantibodybinding 
is responsible for the qualitative shift in TNFRso signaling 
observed. 
Experimental evidence for a causal relationship be- 
tween ligand binding kinetics and bioactivity comes from 
our experiments performed with the MAb 80M2. This anti- 
body possesses the striking feature of being able to hyper- 
stimulate TNFRB~ in the presence of the natural ligand, 
although it is, on its own, neither agonistic nor antagonis- 
tic. Here, we could clearly show that this MAb stabilizes 
TNFbindingtoTNFRso(Figure4). Incellularsystems, how- 
ever, in which TNFRso has no independent signaling capa- 
bility and plays solely a role as a ligand-passing molecule 
for TNFRso, one would expect that 80M2-mediated stabili- 
zation of TNF binding to TNFRso annuls this particular ac- 
cessory effect of TNFRso. In fact, we have observed an 
inhibitory effect of MAb 80M2 when low concentrations 
of TNF were used to induce superoxide anion release in 
human neutrophils (data not shown), which is exclusively 
mediated by TNFRsO (Menegazzi et al., 1994), and cytotox- 
icity in human HeLa cells transfected with TNFRBo, in which 
cytotoxicity is mainly induced byTNFRso (data not shown). 
Similar observations of stabilization of TNF binding to 
TNFRBo and interference of TNFRBo-specific antibodies 
with the mechanism of ligand passing have recently been 
reported (Bigda et al., 1994). 
Why is a TNFReO-linked signaling apparatus of high po- 
tency present in various cells that can be readily activated 
by an experimental stimulus (antibody) but not by the natu- 
ral ligand TNF? We have resolved this question here by 
showing that mTNF, but not sTNF, is a strong activator 
of TNFRBO. This is intelligible because in a situation of 
cell-to-cell contact a juxtaposition of mTNF and TNFRs 
can occur that allows formation of ligand-receptor com- 
plexes of greater stability. It is conceivable that such an 
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interaction is qualitatively distinct from the transient inter- 
action of TNFRBo with sTNF. This interpretation is nicely 
illustrated by the results obtained with a carcinoma cell 
line, Colo205, that responds in a strikingly different man- 
ner to sTNF and mTNF, which produce up-regulation of 
HLA-DR expression and induction of cytotoxicity, respec- 
tively (Figures 1 and 2). 
Activation of TNFRBo by mTNF is not restricted to tumor 
cells. Rather, this finding holds true for all cellular systems 
analyzed in which TNFRBO does not respond or only weakly 
responds to the soluble ligand, but is highly sensitive to 
antibody stimulation. Experiments using mouse thymo- 
cytes expressing the human TNFRso (Figure 6), human 
peripheral blood T lymphocytes, and human endothelial 
cells (Figure 7) indicate that mTNF might also play a crucial 
role in TNF responses of normal tissues as an important 
physiological activator of TNFRso. In fact, previous studies 
have proposed a role for mTNF, rather than sTNF, in im- 
munological reactions such as antileishmanial defense in 
macrophages, T cell-6 cell interaction, and tumor cell kill- 
ing mediated by infiltrating lymphocytes (Birkland et al., 
1992; Aversa et al., 1993; Lopez-Cepero et al., 1994). Ac- 
cording to our data, the action of mTNF, locally restricted 
by cell-to-cell contact, would be both qualitatively and 
quantitatively different from the more promiscuous effects 
of sTNF because of the simultaneous and efficient activa- 
tion of both TNFRs (Figure 8). 
The physiological relevance of TNFRso function is illus- 
trated from very recent data obtained with TNFRBO gene 
knockout mice. Although no apparent gross alterations 
in phenotype and composition of the immune cells were 
noted, and only a slight reduction in sensitivity against 
high dosage LPS shock was found, it had been surprising 
to find a dramatic decrease in sensitivity against tissue 
necrosis caused by repeated subcutaneous injections of 
high doses of murine TNF (Erickson et al., 1994). In a 
similar experimental model, TNF-induced skin necrosis in 
normal mice could be completely blocked by the in vivo 
administration of antagonistic TNFRBo-specific antibodies 
(Sheehan et al., 1995). The absolute TNFRso dependence 
noted in these studies clearly supports an active signaling 
rather than a ligand-passing function of TNFRBo. Although 
in both models tissue necrosis is induced by sTNF, these 
data are not contradictory to a superior activating function 
of mTNF, the induction of which has not been assessed 
in these studies. Here, the demonstrated superiority of 
mTNF in the stimulation of tissue factor expression in 
HUVECs suggests that under physiological conditions 
mTNF interaction with TNFRBO, in combination with TNFRso 
stimulation, might play an important role in inflammatory 
reactions leading to hemorrhagic necrosis. In fact, hemor- 
rhagic necrosis may be initiated by leucocyte-endothelial 
interactions resulting in a conversion of the endothelium 
into a procoagulant state with subsequent thrombotic 
events and vascular leakage. We have shown in indepen- 
dent studies that the initial event is a juxtacrine, TNF- 
dependent process (Schmidt el al., 1995a) that can be 
induced by mTNF expressed on either endothelial cells 
or lymphocytes and that depends on both TNFRso and 
TNFRaO signaling (Schmidt et al., 1995b). 
Finally, the aforementioned novel characteristics of 
TNFRBO disclose what may be a general principle of gener- 
ating diversity of cytokine-induced responses by differen- 
tial receptor activation. We propose that our findings have 
implications for other members of this large ligand family 
and their respective receptors, because it is apparent that 
most other members of the ligand family exist as genuine 
membrane molecules, or as heteromeric molecules in 
membrane-associated forms. Aside from TNF, other solu- 
ble derivatives of this ligand family begin to emerge. For 
example, the soluble form of the Fas ligand has been 
shown to be released by activated peripheral T lympho- 
cytes (Tanaka et al., 1995) and a murine thymoma cell 
line has been shown to secrete soluble CD40 ligand (Armi- 
tage et al., 1992). These soluble ligands are known to be 
bioactive, but adetailed characterization of their spectrum 
of bioactivities awaits further investigation. It is therefore 
possible that differences in signaling capacity of soluble 
versus membrane bound forms of the same ligand will 
soon be unravelled for other receptor ligand systems of 
this family. 
Experimental Procedures 
Cell Culture and Biological Reagents 
The human colon carcinoma cell line Co10205 and Chinese hamster 
ovary (CHO) cells were obtained from the American Type Culture Col- 
lection (Fiockville, MD) and were grown in RPM1 1640 medium supple- 
mented with 5% heat-inactivated fetal calf serum (FCS), 10 mM gluta- 
mine, and 50 pglml each of streptomycin and penicillin (Biochrom, 
Berlin, Federal Republicof Germany).The human rhabdomvosarcoma 
cell line KYM-1 was supplied by M. Sekiguchi (University of Tokyo, 
Tokyo, Japan) and maintained in Click-RPM1 medium (Biochrom) con- 
taining 10% FCS. The cell line NIH3T3 &,, lz,TZ)TNF was provided by Chiron 
Corporation (Emeryville, CA) and maintained in RPM1 medium con- 
taining 10% FCS and 400 pglml G418. T lymphocytes were prepared 
from heparinized whole blood by Ficoll-Hypaque density sedimenta- 
tion as described (Scheurich et al., 1987), stimulated with 1 Kg/ml 
phytohemagglutinin (PHAhn, GIBCO BRL, Gaithersburg, MD), and ex- 
panded in Click-RPM1 containing 10% FCS, P-mercaptoethanol (10d5 
M), and IO U/ml human IL-2(Biotest, Dreieichenhain, Federal Republic 
of Germany) until use. Recombinant human TNF (2 x IO’ Ulmg) was 
provided by Knoll AG (Ludwigshafen, Federal Republic of Germany). 
IFNy was provided from Bender Company (Vienna, Austria). The gen- 
eration and specificity of the MAb H398 (Thoma et al., 1990), MAbs 
Htr-1, Htr-9, Htr-2, and MAb Utr-1 (Brockhaus et al., 1990), MAb 80M2, 
and polyclonal rabbit anti-human TNFRso-specific IgG (Grell et al., 
1993) have all been described. The anti-human TNF MAb (357-101-4) 
was provided by A. Meager (National Institute for Biological Standards 
and Control, Potters Bar, England). 
Generation of CHO Clones Expressing Human TNF 
For construction of the expression vectors for wild-type TNF and the 
uncleavable mutantof humanTNF, an oligonucleotide@‘-ACCTACAA- 
CATGGGCTACTGCCTGGGCCAGAGGGCA-3’) was used to delete 
the DNA sequence encoding amino acids +1 to f12 of the mature, 
17 kDa TNF form. This Al-12 mutation was constructed on a 2.8 kb 
EcoRl fragment of the human TNF gene by using the altered sites in 
vitro mutagenesis system (Promega, Madison, WI). A second muta- 
genesis step was performed on the same fragment to create a Ncol 
restriction site on the ATG translation initiation codon by using a S- 
CATGCTTTCAGTGCCCATGGTGTCC~CC-3’ oligonucleotide. Ei- 
ther the 2 kb wild-type TNF or the mutant 1.8 kb A(1 -12)TNF Ncol- 
EcoRl fragment containing the complete coding region of the human 
TNF gene plus 173 bp of 3’ UTR sequences was inserted into the 
polylinker site of a pEF-BOS-GST expression vector (provided by E. 
Spanopoulou, Rockefeller University, New York, NY), a derivative of 
the pEF-BOS vector (Mizushima and Nagata, 1990) containing an 
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altered polylinker site in between an additional GST-encoding Bglll- 
BamHl fragment of the pGEX-PT expression vector and the polyade- 
nytation signal from the human G-CSF cDNA. The resulting plasmids 
were cotransfected by standard electroporation procedures with 
pMAMneo (Clontech, Palo Alto, CA) into CHO cells. G418-resistant 
cells were sorted for expression of mTNF by cytofluorometric analysis 
using the anti-TNFa-FITC MAb Fluorokine kit (R&D Systems, Minneap- 
olis, MN), according to the recommendations of the manufacturer, and 
a FACStar plus (Becton Dickinson, San Jose, CA). 
Up-Regulation of HLA-DR Antigen Expression 
Co10205 cells or activated human T lymphocytes (day 6-8 after activa- 
tion)wereseeded into24well tissue cultureplates(Greiner, Ntirtingen, 
Federal Republic of Germany) at 3 x 105/well in a final volume of 0.5 
ml of the respective medium (see above) containing 30 pg/ml IFNy 
and 10 U/ml IL-2, respectively. After a 40 hr culture period with the 
different stimuli, cells were harvested, washed twice with phosphate- 
buffered saline containing 2% bovine serum albumine and 0.02% 
NaN3, and suspended in the same buffer including a FITC-labeled 
anti-human HLA-DR monoclonal antibody (Dianova, Hamburg, Fed- 
eral Republic of Germany) or an isotype-matched control antibody. 
Specific fluorescence was determined in duplicates by FACS analysis. 
Generation of Transgenic Mice and Assays 
for Thymocyte Activation 
Thymocytes from 5-week-old transgenic mice expressing a human 
TNFRsa cDNA transgene in their T cell compartment have been em- 
ployed to assess TNFRao function in a standard thymocyte comitogenic 
assay. Preparation of the gene constructs and generation of transgenic 
mice were performed essentially as published (Prober-t et al., 1993) 
and will be described in detail elsewhere (E. D. et al., unpublished 
data). T cell-targeted expression of the human TNFRm transgene was 
achieved by the use of a human CD2 minigene expression cassette 
(Lang et al., 1991). Thymocytes of transgenic mice or nontransgenic 
littermates were cultured in Click-RPM1 medium (Biochrom) supple- 
mented with 1% FCS, 0.5 uglml concanavalin A (Con A, Serva, Heidel- 
berg, Federal Republic of Germany), and antibiotics in 24-well flat- 
bottomed culture plates (Greiner) at 1.2 x 106/0.45 ml on a monolayer 
of CHO control cells or CHOIrl-lPrINF cells in the absence or presence 
of different concentrations of sTNF, or a combination of antagonistic 
TNFRsO-specific antibodies MAb Utr-1 (30 uglml) and polyclonal rabbit 
IgG Fab fragments (50 uglml). After 40 hr at 37°C the concentration 
of murine GM-CSF in the culture supernatants of the individual groups 
was determined by ELISA (Biotrak, Amersham, Braunschweig, Fed- 
eral Republic of Germany). Thereafter, thymocytes were harvested, 
adjusted to the same cell number, and cultured in triplicates in 96-well 
round-bottomed culture plates (Greiner) in medium without Con A in 
the presence of 10 uCi/ml PH]thymidine (82 Cilmmol, Amersham). 
The purity of thymocytes in the individual assay groups was >99.5%, 
as controlled by FAGS analysis. After 8 hr, cells were harvested onto 
glass fiber filters, and incorporated radioactivity was determined using 
a digital autoradiograph (Berthold, Wildbad, Federal Republic of Ger- 
many). Normal standard deviation was <150/a. Specific IL-2 receptor 
a chain (CD25) surface expression of thymocytes was determined by 
FACS analysis as described above using FITC-conjugated rat anti- 
mouse CD25 and isotype-matched control antibodies (PharMingen, 
Hamburg, Federal Republic of Germany). 
Tissue Factor Activity of HUVECs 
HUVECs were prepared as described (Thornton et al., 1983) and cul- 
tured in EGM medium (PromoCell, Heidelberg, Federal Republic of 
Germany). Expression of tissue factor was assessed as described 
previously (Clauss et al., 1990). In brief, cultures with TNF or added 
cells (or with both) in MDCB 131 medium (GIBCO), containing 10 mM 
HEPES (pH 7.4) 10% FCS, 100 U/ml penicillin, 100 &ml streptomy- 
cin, 2 mM glutamine, 2.5 mg/ml fungizone (GIBCO) were incubated 
for 3 hr at 37°C. For studies with neutralizing antibodies (50-100 ugl 
ml), cells were preincubated for 30 min at room temperature before 
addition of cells, cytokines, or both. Assays were carried out with whole 
cells obtained in suspension following scraping from the dish. Citrated 
human plasma was added, and the clotting time was measured after 
recalcification. Tissue factor equivalents were calculated using a stan- 
dard curve of purified human tissue factor (Clauss et al., 1990). 
Cytotoxicity and Proliferation Assays 
Assays were carried out essentially as described (Grell et al., 1993). 
In brief, KYM-1 cells (1 x 104/well) or Co10205 cells (1.5 x 104/well) 
were seeded into 96-well microtiter plates in 100 nl of the respective 
medium (see above) and allowed to grow overnight before addition of 
the different substances to a final volume of 200 ~1. After 18 hr (KYM-1) 
or 40 hr (Colo205) of culture, metabolic activity was determined by the 
MTT method. For analysisof mTNF-mediated cytotoxicity in cell-to-cell 
killing experiments, the respective CHO clones were irradiated (5000 
rad), washed extensively, and seeded into microtiter plates overnight 
(2 x lo4 cells/well). Subsequently, Co10205 cells (1 x 104/well) were 
added, and treatment with the respective stimuli was performed in six 
replicate wells for 30 hr including PH]thymidine (Amersham; 0.5 uCi/ 
well) during the last 6 hr. Cells were harvested onto glass fiber filters 
and lysed by distilled water, and cell-bound radioactivity at the filter 
was measured in a liquid scintillation counter. 
Binding Assays 
TNF was labeled with ‘? by the chloramine-T method, and binding 
assays were performed essentially as described (Dower et al., 1985). 
For dissociation kinetics, cells were incubated for 1 hr with 0.5 nM 
rz51]TNF in culture medium in the presence or absence of MAb 80M2 
(1 ug/ml) at 4OC. Subsequently, cells were suspended in the presence 
50 nM unlabeled TNF at 37OC for several time periods, and cell-bound 
[‘?]TNF was determined after centrifugation of cells through a phthal- 
ate oil mixture. The timepoint at which the cells were resuspended 
was taken as the start of the reaction, and the corresponding value 
was set at 100%. For association kinetics, cells were preincubated 
with MAb 80M2 or medium and then incubated for different time peri- 
ods with 0.5 nM rz51]TNF at 37OC. Cell-bound radioactivity was deter- 
mined as described above. The respective dissociation constant was 
computed from the ratio of the dissociation rate constant to the associa- 
tion rate constant calculated from the net association rate. 
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